CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the

Point32Health will dramatically change how and when it pays for Zepbound — the insurer’s preferred GLP-1 weight-loss drug— when used to treat overweight or obesity.